Denali Therapeutics (DNLI) said Wednesday the US Food and Drug Administration has given breakthrough therapy designation for tividenofusp alfa to treat people with Hunter syndrome, a rare genetic disease.
The designation was created to quicken the development and review of candidate drugs to treat serious or life-threatening diseases, the company said.
The label is in addition to fast track designation, orphan drug designation, and rare pediatric disease designation that were all previously given by the FDA for tividenofusp alfa to treat Hunter syndrome, Denali added.
Denali said it plans to file a biologics license application for tividenofusp alfa early this year.
The company's shares were rising 1.6% in recent trading.
Price: 21.52, Change: +0.34, Percent Change: +1.61
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。